Regenxbio Inc (NASDAQ:RGNX) CFO Vittal Vasista sold 5,000 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the chief financial officer now directly owns 87,277 shares in the company, valued at approximately $2,618,310. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Vittal Vasista also recently made the following trade(s):
- On Monday, October 16th, Vittal Vasista sold 5,000 shares of Regenxbio stock. The stock was sold at an average price of $33.25, for a total value of $166,250.00.
Shares of Regenxbio Inc (NASDAQ:RGNX) traded up $0.55 during trading hours on Friday, hitting $30.45. The stock had a trading volume of 642,016 shares, compared to its average volume of 465,068. Regenxbio Inc has a twelve month low of $16.30 and a twelve month high of $36.45. The stock has a market capitalization of $931.24, a P/E ratio of -11.28 and a beta of -0.88.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The business had revenue of $1.34 million for the quarter. research analysts predict that Regenxbio Inc will post -2.71 earnings per share for the current fiscal year.
Several large investors have recently modified their holdings of RGNX. State Street Corp lifted its position in shares of Regenxbio by 178.1% in the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock valued at $17,399,000 after acquiring an additional 564,129 shares in the last quarter. GMT Capital Corp lifted its position in Regenxbio by 1,086.2% during the second quarter. GMT Capital Corp now owns 609,700 shares of the biotechnology company’s stock worth $12,346,000 after buying an additional 558,300 shares during the period. Redmile Group LLC lifted its position in Regenxbio by 35.4% during the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after buying an additional 449,540 shares during the period. Citadel Advisors LLC lifted its position in Regenxbio by 65.4% during the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after buying an additional 366,289 shares during the period. Finally, RTW Investments LP lifted its position in Regenxbio by 20.9% during the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock worth $50,710,000 after buying an additional 266,235 shares during the period. Institutional investors and hedge funds own 68.73% of the company’s stock.
RGNX has been the topic of a number of research analyst reports. Bank of America reiterated a “buy” rating and set a $38.00 target price (up from $33.00) on shares of Regenxbio in a research report on Monday, October 9th. Chardan Capital boosted their target price on Regenxbio from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. BidaskClub upgraded Regenxbio from a “hold” rating to a “buy” rating in a research report on Thursday, December 7th. Raymond James Financial reiterated a “buy” rating on shares of Regenxbio in a research report on Friday, January 5th. Finally, TheStreet downgraded Regenxbio from a “c” rating to a “d+” rating in a research report on Tuesday, November 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $42.43.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.